|
1.
|
Weitz J, Koch M, Debus J, Hohler T, Galle
PR and Buchler MW: Colorectal cancer. Lancet. 365:153–165. 2005.
View Article : Google Scholar
|
|
2.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
3.
|
Roberts RB, Arteaga CL and Threadgill DW:
Modeling the cancer patient with genetically engineered mice:
prediction of toxicity from molecule-targeted therapies. Cancer
Cell. 5:115–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Semenza GL: Hypoxia and cancer. Cancer
Metastasis Rev. 26:223–224. 2007. View Article : Google Scholar
|
|
5.
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
6.
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
8.
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Vihanto MM, Plock J, Erni D, Frey BM, Frey
FJ and Huynh-Do U: Hypoxia up-regulates expression of Eph receptors
and ephrins in mouse skin. FASEB J. 19:1689–1691. 2005.PubMed/NCBI
|
|
10.
|
Yamashita T, Ohneda K, Nagano M, et al:
Hypoxia-inducible transcription factor-2alpha in endothelial cells
regulates tumor neovascularization through activation of ephrin A1.
J Biol Chem. 283:18926–18936. 2008. View Article : Google Scholar
|
|
11.
|
Holzman LB, Marks RM and Dixit VM: A novel
immediate-early response gene of endothelium is induced by
cytokines and encodes a secreted protein. Mol Cell Biol.
10:5830–5838. 1990.PubMed/NCBI
|
|
12.
|
Bartley TD, Hunt RW, Welcher AA, et al:
B61 is a ligand for the ECK receptor protein-tyrosine kinase.
Nature. 368:558–560. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Brantley DM, Cheng N, Thompson EJ, et al:
Soluble Eph A receptors inhibit tumor angiogenesis and progression
in vivo. Oncogene. 21:7011–7026. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Pandey A, Shao H, Marks RM, Polverini PJ
and Dixit VM: Role of B61, the ligand for the Eck receptor tyrosine
kinase, in TNF-alpha-induced angiogenesis. Science. 268:567–569.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Deroanne C, Vouret-Craviari V, Wang B and
Pouyssegur J: EphrinA1 inactivates integrin-mediated vascular
smooth muscle cell spreading via the Rac/PAK pathway. J Cell Sci.
116:1367–1376. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Cheng N, Brantley DM, Liu H, et al:
Blockade of EphA receptor tyrosine kinase activation inhibits
vascular endothelial cell growth factor-induced angiogenesis. Mol
Cancer Res. 1:2–11. 2002. View Article : Google Scholar
|
|
17.
|
Ogawa K, Pasqualini R, Lindberg RA, Kain
R, Freeman AL and Pasquale EB: The ephrin-A1 ligand and its
receptor, EphA2, are expressed during tumor neovascularization.
Oncogene. 19:6043–6052. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Abraham S, Knapp DW, Cheng L, et al:
Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary
bladder. Clin Cancer Res. 12:353–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Brantley-Sieders DM, Fang WB, Hwang Y,
Hicks D and Chen J: Ephrin-A1 facilitates mammary tumor metastasis
through an angiogenesis-dependent mechanism mediated by EphA
receptor and vascular endothelial growth factor in mice. Cancer
Res. 66:10315–10324. 2006. View Article : Google Scholar
|
|
20.
|
Noblitt LW, Bangari DS, Shukla S, et al:
Decreased tumorigenic potential of EphA2-overexpressing breast
cancer cells following treatment with adenoviral vectors that
express EphrinA1. Cancer Gene Ther. 11:757–766. 2004. View Article : Google Scholar
|
|
21.
|
Nakamura R, Kataoka H, Sato N, et al:
EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci.
96:42–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Liu DP, Wang Y, Koeffler HP and Xie D:
Ephrin-A1 is a negative regulator in glioma through down-regulation
of EphA2 and FAK. Int J Oncol. 30:865–871. 2007.PubMed/NCBI
|
|
23.
|
Nasreen N, Mohammed KA, Lai Y and Antony
VB: Receptor EphA2 activation with ephrinA1 suppresses growth of
malignant mesothelioma (MM). Cancer Lett. 258:215–222. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Uemura M, Yamamoto H, Takemasa I, et al:
Jumonji domain containing 1A is a novel prognostic marker for
colorectal cancer: in vivo identification from hypoxic tumor cells.
Clin Cancer Res. 16:4636–4646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Yamamoto H, Kondo M, Nakamori S, et al:
JTE-522, a cyclooxygenase-2 inhibitor, is an effective
chemopreventive agent against rat experimental liver fibrosis.
Gastroenterology. 125:556–571. 2003.PubMed/NCBI
|
|
26.
|
Okami J, Yamamoto H, Fujiwara Y, et al:
Overexpression of cyclooxygenase-2 in carcinoma of the pancreas.
Clin Cancer Res. 5:2018–2024. 1999.PubMed/NCBI
|
|
27.
|
Nagel S, Schmidt M, Thiede C, Huhn D and
Neubauer A: Quantification of Bcr-Abl transcripts in chronic
myelogenous leukemia (CML) using standardized, internally
controlled, competitive differential PCR (CD-PCR). Nucleic Acids
Res. 24:4102–4103. 1996. View Article : Google Scholar
|
|
28.
|
Hayashi N, Yamamoto H, Hiraoka N, et al:
Differential expression of cyclooxygenase-2 (COX-2) in human bile
duct epithelial cells and bile duct neoplasm. Hepatology.
34:638–650. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Takemasa I, Yamamoto H, Sekimoto M, et al:
Overexpression of CDC25B phosphatase as a novel marker of poor
prognosis of human colorectal carcinoma. Cancer Res. 60:3043–3050.
2000.PubMed/NCBI
|
|
30.
|
Holm R, De Putte GV, Suo Z, Lie AK and
Kristensen GB: Expressions of EphA2 and EphrinA-1 in early squamous
cell cervical carcinomas and their relation to prognosis. Int J Med
Sci. 5:121–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Potla L, Boghaert ER, Armellino D, Frost P
and Damle NK: Reduced expression of EphrinA1 (EFNA1) inhibits
three-dimensional growth of HT29 colon carcinoma cells. Cancer
Lett. 175:187–195. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Brennan DJ, Jirstrom K, Kronblad A, et al:
CA IX is an independent prognostic marker in premenopausal breast
cancer patients with one to three positive lymph nodes and a
putative marker of radiation resistance. Clin Cancer Res.
12:6421–6431. 2006. View Article : Google Scholar
|
|
33.
|
Kizaka-Kondoh S, Inoue M, Harada H and
Hiraoka M: Tumor hypoxia: a target for selective cancer therapy.
Cancer Sci. 94:1021–1028. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Noda T, Yamamoto H, Takemasa I, et al:
PLOD2 induced under hypoxia is a novel prognostic factor for
hepatocellular carcinoma after curative resection. Liver Int.
32:110–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
